BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 466 filers reported holding BIO-TECHNE CORP in Q1 2021. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,134,675 | -33.2% | 31,360 | -19.9% | 0.00% | -50.0% |
| Q2 2023 | $3,195,243 | +13.5% | 39,143 | +3.2% | 0.00% | +33.3% |
| Q1 2023 | $2,814,620 | -57.0% | 37,938 | -52.0% | 0.00% | -62.5% |
| Q4 2022 | $6,546,691 | +12.6% | 78,990 | +285.7% | 0.01% | +14.3% |
| Q3 2022 | $5,816,000 | -28.4% | 20,479 | -12.7% | 0.01% | -22.2% |
| Q2 2022 | $8,127,000 | +0.2% | 23,446 | +9.7% | 0.01% | +12.5% |
| Q1 2022 | $8,113,000 | -35.9% | 21,368 | -12.6% | 0.01% | -33.3% |
| Q4 2021 | $12,649,000 | +5.7% | 24,450 | -1.0% | 0.01% | 0.0% |
| Q3 2021 | $11,969,000 | -4.4% | 24,701 | -11.2% | 0.01% | 0.0% |
| Q2 2021 | $12,518,000 | +20.7% | 27,801 | +2.4% | 0.01% | +9.1% |
| Q1 2021 | $10,369,000 | +39.2% | 27,149 | +15.7% | 0.01% | +37.5% |
| Q4 2020 | $7,448,000 | +29.2% | 23,455 | +0.8% | 0.01% | +14.3% |
| Q3 2020 | $5,765,000 | +0.0% | 23,270 | +6.6% | 0.01% | -12.5% |
| Q2 2020 | $5,764,000 | -23.9% | 21,829 | -45.4% | 0.01% | +33.3% |
| Q1 2020 | $7,576,000 | +37.1% | 39,950 | +58.8% | 0.01% | -14.3% |
| Q4 2019 | $5,524,000 | +22.5% | 25,163 | +9.2% | 0.01% | +16.7% |
| Q3 2019 | $4,508,000 | +51.9% | 23,041 | +61.8% | 0.01% | 0.0% |
| Q2 2019 | $2,968,000 | -0.9% | 14,238 | -5.6% | 0.01% | -14.3% |
| Q1 2019 | $2,994,000 | +4.1% | 15,080 | -24.1% | 0.01% | 0.0% |
| Q4 2018 | $2,875,000 | -29.3% | 19,864 | -0.4% | 0.01% | -12.5% |
| Q3 2018 | $4,069,000 | -1.5% | 19,937 | -28.6% | 0.01% | -11.1% |
| Q2 2018 | $4,130,000 | +11.0% | 27,917 | +13.3% | 0.01% | +12.5% |
| Q1 2018 | $3,721,000 | – | 24,635 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |